Cumberland Pharmaceuticals Inc. (CPIX) Company Bio
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.
CPIX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Cumberland Pharmaceuticals Inc. To summarize, we found that Cumberland Pharmaceuticals Inc ranked in the 27th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 53.33%. The most interesting components of our discounted cash flow analysis for Cumberland Pharmaceuticals Inc ended up being:
Interest coverage, a measure of earnings relative to interest payments, is -18.66; that's higher than only 7.22% of US stocks in the Healthcare sector that have positive free cash flow.
Cumberland Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
PKI, RMD, XRAY, ZTS, and ILMN can be thought of as valuation peers to CPIX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical…
Cumberland Pharmaceuticals, Inc. (CPIX) Q2 2020 Earnings Conference Call August 11, 2020 04:30 PM ET Company Participants Erin Gull - IR A. J. Kazimi - CEO Marty Cearnal - Chief Commercial Officer Michael Bonner - CFO Conference Call Participants Andrew D'Silva - B. Riley FBR Presentation Operator Thanks to everyone...
NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently published in the Journal of Orthopedic Trauma. Results demonstrate Caldolor®…